Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms

Ingo K. Mellinghoff, Susan M. Chang, Kurt A. Jaeckle, Martin van den Bent

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
26 Downloads (Pure)
Original languageEnglish
Pages (from-to)95-111
Number of pages17
JournalHematology-Oncology Clinics of North America
Volume36
Issue number1
Early online date18 Nov 2021
DOIs
Publication statusPublished - Feb 2022

Bibliographical note

Funding Information:
I.K. Mellinghoff reports serving as a consultant for Agios Pharmaceuticals, Inc, Black Diamond, DC Europa, Debiopharm, Puma Biotechnology, and Voyager, and research grants from Amgen , Eli Lilly , and General Electric . M. van den Bent reports serving as a consultant for Agios Pharmaceuticals, Karyopharm, Cellgene, Nerviano, Carthera, and Genenta. S.M. Chang reports institutional research support from Agios Pharmaceuticals .

Funding Information:
Funded by: VSNU2020.This work was supported by 1 R35 NS105109 03 (I.K. Mellinghoff), P30CA008748 (I.K. Mellinghoff), and Cycle of Survival (I.K. Mellinghoff). I.K. Mellinghoff reports serving as a consultant for Agios Pharmaceuticals, Inc, Black Diamond, DC Europa, Debiopharm, Puma Biotechnology, and Voyager, and research grants from Amgen, Eli Lilly, and General Electric. M. van den Bent reports serving as a consultant for Agios Pharmaceuticals, Karyopharm, Cellgene, Nerviano, Carthera, and Genenta. S.M. Chang reports institutional research support from Agios Pharmaceuticals.

Funding Information:
This work was supported by 1 R35 NS105109 03 (I.K. Mellinghoff), P30CA008748 (I.K. Mellinghoff), and Cycle of Survival (I.K. Mellinghoff).

Cite this